Semaglutide and walking capacity in symptomatic PAD and type 2 diabetes patients: the STRIDE trial Selected in The Lancet by Xavier Devoisin This phase 3b, double-blind, randomised, placebo-controlled trial assessed the effect of semaglutide on walking capacity in patients with symptomatic peripheral artery disease (PAD) and type 2 diabetes
#GLP1 receptor agonists are supported by preclinical and observational evidence for reducing addictive behaviors, particularly alcohol and nicotine use
Partnering with a vetted, compliant pharmacy is the only way to minimize risks and ensure your patients receive a quality product
But if I do strength training and Im building lean muscle, that muscle is requiring more energy 24 hours a day, 7 days a week
Niacinamide 2% : Regulates melanin transfer, promotes collagen, and reduces moisture loss
The UK cost-of-living crisis and its effect on students at a British medical school